Thus, tumours with STK11 mutations seem to be associated with a worse outcome of ICB therapy and it has also been shown that co‐occurrence of STK11 with, for example, KEAP1 or KRAS may be prognostic rather than predictive.37, 38. This evidence concerns the gene STK11 and neoplasm.